Constipation on a GLP-1 Microdose: Why Transit Slows, Why It Lasts 47 Days, and What Actually Moves It

A man in his fifties starts a low weekly dose of tirzepatide and sails through the first ten days. A little queasiness after a large dinner, nothing more. By day sixteen he notices he has not had a bowel movement since the weekend. By day twenty the stools are small, hard, and an effort, and there is a bloated heaviness after lunch that was not there before. He is eating about half of what he used to. He has also, without registering it, stopped eating the two slices of wholegrain toast, the apple, and the lentil soup that used to supply most of his fibre, because none of them appeal any more and a small plate of chicken fills him.

His experience is the textbook one, and the timing matters. Nausea is the side effect of the first two weeks, driven by the stomach emptying more slowly, and the stomach adapts. Constipation is the side effect of the second month and beyond, because it has three drivers that do not adapt on their own: the medication slows movement along the small intestine and colon, the smaller diet removes most of the fibre that gives the colon something to push against, and the same medication suppresses thirst so the stool that forms is dry. Wharton and colleagues quantified the consequence in 2022 from the STEP 1 data: a median nausea episode on semaglutide 2.4 mg lasted 8 days, and a median constipation episode lasted 47.

This article covers what the prescribing information and the trials report about constipation across the GLP-1 class, the three mechanisms and how they stack, the fibre arithmetic that makes a 1,200-calorie diet a low-fibre diet by default, what the trials of psyllium, prunes, and kiwifruit show, what changes on a microdose, and a table that separates the constipation a bag of psyllium fixes from the abdomen that needs same-day assessment.

How common is constipation on a GLP-1 medication?

Constipation is roughly twice as common on a GLP-1 medication as on placebo, and it appears in every label in the class. The Wegovy prescribing information, which pools the STEP trials of semaglutide 2.4 mg, lists constipation at 24 percent versus 11 percent on placebo, behind nausea at 44 percent and diarrhoea at 30 percent and level with vomiting at 24 percent. The Saxenda label for liraglutide 3 mg reports 19 percent versus 9 percent. The Zepbound label for tirzepatide reports constipation at 11 to 17 percent across the 5, 10, and 15 mg doses versus 6 percent on placebo, and in SURMOUNT-1 the 5 and 10 mg arms reported slightly more constipation than the 15 mg arm, which the authors did not explain. Even the lower diabetes doses of semaglutide register it: the Ozempic label lists constipation at 3 to 5 percent versus 1 percent.

Two features of the data are easy to miss. First, the placebo rate is not trivial. One in ten people on placebo in a 68-week trial reported constipation, because constipation is common in the general population and more common in people with obesity, and the drug roughly doubles that background. Second, the trials counted whether an event was reported, not how long it went on. In the STEP 1 analysis, most gastrointestinal events were mild or moderate and few led to discontinuation: 4.3 percent of semaglutide participants stopped for gastrointestinal reasons versus 0.7 percent on placebo. Constipation was rarely the reason anyone stopped. It was, however, the event that stayed.

Constipation does not appear in the warnings and precautions section of any GLP-1 label as a direct effect, but ileus does. Ileus, a slowing or stopping of intestinal movement, was added to the Ozempic and Wegovy prescribing information in 2023 on the basis of postmarketing reports, and the Zepbound label carries the same wording. That placement is the map for this article: constipation is a common nuisance the label treats as expected, and ileus is the rare condition worth watching for underneath it.

How long does constipation last on a GLP-1 medication?

Far longer than nausea, and this is the single most useful number in the article. Wharton and colleagues published a tolerability analysis of STEP 1 in Diabetes, Obesity and Metabolism in 2022, using the daily adverse event records of 1,961 participants over 68 weeks. The median duration of a nausea episode on semaglutide 2.4 mg was 8 days. Vomiting lasted a median of 2 days and diarrhoea 3. Constipation lasted a median of 47 days. Nausea, vomiting, and diarrhoea also clustered tightly around the dose escalation steps in the first 20 weeks and then thinned out. Constipation was more evenly spread and kept appearing well into the maintenance phase.

The difference in duration reflects a difference in cause. Nausea comes mostly from delayed gastric emptying, and the stomach's response to a long-acting GLP-1 agonist wears off with continued exposure. Nauck and colleagues showed in 2011 that the gastric emptying delay produced by liraglutide was largely gone after a few weeks of daily dosing, a tachyphylaxis that explains why nausea fades while appetite suppression does not. Constipation is not mainly a stomach problem. Its drivers, described in the next section, sit further down the gut and in the diet, and none of them fade on a fixed schedule. The stool stays small, dry, and slow for as long as the fibre stays low and the fluid stays short, which in an unmanaged protocol is indefinitely.

The practical reading of the 47-day figure is that waiting it out is a poor strategy. A six-to-seven-week episode is what happens when nothing is changed. People who set a fibre target and a fluid target in the first week of a protocol, before the bowel slows, tend to report a short dip in the second and third weeks and a return to their baseline pattern by the end of the first month, which is the shape drawn in the timeline chart later in this article.

Why does a GLP-1 medication cause constipation?

A GLP-1 medication causes constipation by slowing the gut directly and by shrinking the diet that feeds it, and the two effects compound. The direct effect is on motility. GLP-1 is released from the lower small intestine after a meal and acts as an "ileal brake," signalling the stomach and upper gut to slow down so that nutrients are absorbed rather than rushed through. A GLP-1 receptor agonist delivers that brake signal continuously. Hellström and colleagues showed in 2008 that infusing GLP-1 into people with irritable bowel syndrome reduced motor activity in the colon and slowed transit, and Halim and colleagues reported in 2018 that GLP-1 inhibited the motility of the human small intestine by acting on nerves in the gut wall rather than on the muscle itself. Both effects were measured within hours, independent of any change in food intake.

The second driver is fibre, and it is the one most people underestimate. Stool bulk comes almost entirely from undigested fibre and the water it holds and the bacteria that ferment it. A colon receiving a good volume of fibre-rich residue stretches, and that stretch triggers the coordinated contractions that move stool along. A person who was eating 2,200 calories and drops to 1,200 removes close to half of their fibre unless food choices change, and in practice the foods that go first on a GLP-1 medication are often the bulky, high-fibre ones: the bread, the fruit, the bowl of oats, the beans. What remains is a small, protein-forward plate that produces a small, dense residue. The colon has less to push and less reason to push it.

The third driver is fluid. GLP-1 receptor agonists suppress thirst along with appetite, and most fluid in an ordinary diet arrives with meals. When meals shrink, water intake falls and thirst does not compensate. The colon's main job is to reclaim water from stool, and stool that spends 47 days moving slowly through a colon while the body is short of water becomes hard. Add the reduced physical activity that often accompanies a lower-energy first month and the effect of any iron, calcium, or opioid-containing medication already in the picture, and the reasons the bowel stops are fully accounted for without any need for the drug to do something mysterious.

How much fibre does a GLP-1 diet actually deliver?

Much less than the recommendation, and the shortfall grows as the diet shrinks. The Dietary Guidelines for Americans set the adequate intake at 14 grams of fibre per 1,000 calories, which works out to about 25 grams a day for most women and 38 for most men. Actual intake in the United States and the United Kingdom averages 15 to 17 grams a day at around 2,200 calories, a density closer to 8 grams per 1,000 calories. That gap exists before any medication. A GLP-1 medication then cuts calories without changing the density, so a person at 1,400 calories on ordinary choices lands at about 11 grams and a person at 1,100 calories at about 8, a third of the target.

Closing the gap on a small intake means raising density rather than volume, because volume is exactly what the medication has removed. Legumes are the most efficient source: half a cup of cooked lentils carries about 8 grams of fibre in 115 calories. A tablespoon of chia seeds adds 5 grams for 60 calories, a cup of raspberries 8 grams for 65, an ounce of almonds 3.5 grams for 165, and half a cup of cooked oats about 4 grams for 80. Building each small meal around one of those, with a vegetable alongside, gets a 1,300-calorie day to the low twenties. The remaining few grams are what a supplement is for.

The order matters. Fibre added quickly to a gut that has slowed produces gas and bloating, which on a GLP-1 medication is already a complaint, and insoluble fibre such as wheat bran added without fluid can make hard stool harder. The workable sequence is fluid first, to a target of two litres a day tracked on a bottle rather than estimated; then soluble, gel-forming fibre such as psyllium, oats, and chia, stepped up over a week; then the bulkier insoluble sources. Fibre without water is the most common reason a first attempt fails.

What does the evidence say about psyllium, prunes, and kiwifruit?

All three have randomised trial evidence in chronic constipation, and each suits a small diet because the effective dose is a few dozen calories. Psyllium is the most studied. Van der Schoot and colleagues published a systematic review and meta-analysis of 16 randomised trials in the American Journal of Clinical Nutrition in 2022 and found that fibre supplementation increased stool frequency and softened stool consistency in adults with chronic constipation, with the clearest benefit from psyllium at doses of 10 grams a day or more taken for at least four weeks. Psyllium is a soluble fibre that forms a gel and holds water in the stool, which is exactly the property a dry, slow-moving GLP-1 stool lacks. The usual approach is a teaspoon in a full glass of water once a day, increased to twice a day over a week.

Prunes have a head-to-head trial against psyllium. Attaluri and colleagues reported in Alimentary Pharmacology and Therapeutics in 2011 a crossover study of 40 adults with chronic constipation who took either 100 grams of prunes a day, about ten prunes, or 11 grams of psyllium a day for three weeks each. Prunes produced 3.5 complete spontaneous bowel movements a week compared with 2.8 on psyllium, and stool consistency improved more on prunes as well. Prunes work through fibre, sorbitol, and phenolic compounds together, and 100 grams is about 240 calories, which is affordable on most GLP-1 diets if it displaces something with less to offer.

Kiwifruit is the newest of the three. Gearry and colleagues published a multicentre randomised trial in the American Journal of Gastroenterology in 2023 comparing two green kiwifruit a day with 7.5 grams of psyllium over four weeks in adults with functional constipation or constipation-predominant irritable bowel syndrome. Kiwifruit increased complete spontaneous bowel movements by more than 1.5 a week, a clinically meaningful change, with significantly less abdominal discomfort and bloating than psyllium. Two kiwifruit are about 90 calories. For someone on a GLP-1 medication who is already bloated, the lower gas burden is a real advantage, and the fruit needs no glass of water to work.

Is constipation milder on a GLP-1 microdose?

Milder on the transit side, roughly the same on the diet side, and the distinction is worth understanding. The motility effect of a GLP-1 receptor agonist scales with dose, which is why every label starts at a fraction of the maintenance dose and climbs in steps of four weeks or more. The phase 2 dose-ranging study of semaglutide reported by O'Neil and colleagues in the Lancet in 2018 showed gastrointestinal adverse events rising across the dose range, and the SURMOUNT and STEP escalation schedules exist because a bowel that is introduced to the drug slowly tolerates it better than one that is not. A microdose at a quarter to a third of a standard maintenance dose applies a correspondingly lighter brake to the small intestine and colon.

The fibre and fluid deficit, however, begins at whatever dose starts to suppress appetite, and that is the whole point of a microdose. Someone eating 1,300 calories on a low dose has removed the same fibre and the same meal-time water as someone eating 1,300 calories on a full dose. The stool is slightly less slow, but it is just as small and just as dry. In practice that means constipation on a microdose tends to arrive later, run milder, and respond faster to a fibre and fluid routine, but it does not disappear, and someone who was already prone to constipation before starting should assume it will need managing.

No trial has reported constipation rates at true microdose levels, and the honest position is extrapolation from the escalation phases of the standard trials, where the starting doses produced fewer gastrointestinal events than the maintenance doses. The advantage a microdose offers is that the drug-driven share of the problem is smaller, so the diet-driven share, which is the part a person can control, becomes the majority of it. That is a favourable arithmetic: the fixes are a fibre target, a fluid target, and a daily walk, and they cover most cases before a laxative is discussed.

Which constipation on a GLP-1 medication needs a clinician?

Most constipation on a GLP-1 protocol responds within a week to a fibre floor, a fluid floor, and a daily walk, and the constipation that survives those plus an osmotic laxative is the one to report. Constipation that began sharply with a dose increase is a prescriber question, since holding the dose or stepping back is the usual fix. Several days without a bowel movement together with a swollen and tender abdomen, repeated vomiting, an inability to pass gas, or severe pain is not a laxative question at all and needs same-day or emergency assessment, because ileus has been reported with this drug class and is listed in the prescribing information. Pain under the right ribs after meals belongs in the same urgent category, because gallstones are more common during rapid weight loss and the symptoms overlap.

The table below matches the common patterns to what most often lies behind them and what to do next. The useful principle across the first four rows is that constipation from low fibre and low fluid resolves within days of correcting them, and that resolution is itself the confirmation. Constipation that survives the correction has a different cause, and an osmotic laxative such as polyethylene glycol is the appropriate next step rather than more fibre.

The drug slows the road. The diet decides what travels on it.

A GLP-1 receptor agonist applies a continuous brake to the small intestine and colon, and there is no dietary trick that removes it. What the diet controls is everything else: the bulk of fibre that gives the colon something to move, the water that keeps it soft, and the walk after lunch that reminds the gut it is still in business. The STEP 1 median of 47 days is what constipation looks like when a person waits for it to pass. The alternative is to set the fibre and fluid targets in the first week, before the bowel slows, treat two kiwifruit or ten prunes as part of the protocol rather than a snack, and keep an osmotic laxative in the cupboard for the week the routine is not enough. A microdose makes the brake lighter. It does not make the fibre appear.

Frequently asked questions

Clinical references

1. Novo Nordisk. Wegovy (semaglutide) injection 2.4 mg: prescribing information, adverse reactions and warnings and precautions, ileus. US Food and Drug Administration; 2021, with subsequent revisions including 2023.
2. Eli Lilly. Zepbound (tirzepatide) injection: prescribing information, adverse reactions and warnings and precautions. US Food and Drug Administration; 2023, with subsequent revisions.
3. Novo Nordisk. Saxenda (liraglutide) injection 3 mg: prescribing information, adverse reactions. US Food and Drug Administration; 2014, with subsequent revisions.
4. Novo Nordisk. Ozempic (semaglutide) injection: prescribing information, adverse reactions and warnings and precautions, ileus. US Food and Drug Administration; 2017, with subsequent revisions including 2023.
5. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism. 2022;24(1):94-105.
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
8. O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649.
9. Hellström PM, Näslund E, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterology and Motility. 2008;20(6):649-659.
10. Halim MA, Degerblad M, Sundbom M, et al. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. Journal of Clinical Endocrinology and Metabolism. 2018;103(2):575-585.
11. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.
12. van der Schoot A, Drysdale C, Whelan K, Dimidi E. The effect of fiber supplementation on chronic constipation in adults: an updated systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition. 2022;116(4):953-969.
13. Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Alimentary Pharmacology and Therapeutics. 2011;33(7):822-828.
14. Gearry R, Fukudo S, Barbara G, et al. Consumption of 2 green kiwifruits daily improves constipation and abdominal comfort: results of an international multicenter randomized controlled trial. American Journal of Gastroenterology. 2023;118(6):1058-1068.
15. US Department of Agriculture and US Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th edition; December 2020.
16. Quagliani D, Felt-Gunderson P. Closing America's fiber intake gap: communication strategies from a food and fiber summit. American Journal of Lifestyle Medicine. 2017;11(1):80-85.